Detalhes bibliográficos
| Ano de defesa: |
2014 |
| Autor(a) principal: |
Krause, Gabriele Catyana
 |
| Orientador(a): |
Oliveira, Jarbas Rodrigues de
|
| Banca de defesa: |
Não Informado pela instituição |
| Tipo de documento: |
Dissertação
|
| Tipo de acesso: |
Acesso aberto |
| Idioma: |
por |
| Instituição de defesa: |
Pontifícia Universidade Católica do Rio Grande do Sul
|
| Programa de Pós-Graduação: |
Programa de Pós-Graduação em Biologia Celular e Molecular
|
| Departamento: |
Faculdade de Biociências
|
| País: |
BR
|
| Palavras-chave em Português: |
|
| Área do conhecimento CNPq: |
|
| Link de acesso: |
http://tede2.pucrs.br/tede2/handle/tede/5499
|
Resumo: |
Hepatocellular carcinoma (HCC) is the most frequent primary tumor of the liver, and is currently one of the major neoplastic diseases, representing 85% of primary liver tumors and is the third leading cause of cancer-related death. The development of the majority of hepatocellular carcinomas related to the presence of a disease resulting from cirrhosis, such as hepatitis B and C. Its incidence has increased in recent years due to the number of patients with infections caused by hepatitis C. The aim of this study was investigate the in vitro effect of fructose-1,6-bisphosphate (FBP) on the growth of HepG2 cells, used as a model to hepatocellular carcinoma. The results showed that the FBP decreases cell proliferation in a dose-dependent manner, not being caused by cell cycle arrest or apoptosis verified by flow cytometry. It was observed that at 72 h of treatment FBP decreased levels of IL-8, which is closely related to the tumor progression and the generation of reactive oxygen species. Moreover, FBP decreased oxidative stress by increasing the levels of catalase and decrease TBARS, this effect is possibly caused by the result of low IL- 8. These findings demonstrated that the FBP may be a potential anticancer agent for the treatment of HCC. |
